PTH and X-linked hypophosphatemia: Even if it is known that serum PTH levels tend to be elevated (54.4–100%), and FGF23 levels are abnormally high (74.2–100%) in most patients with XLH [1, 19, 28], the correlation between these two factors and the response to burosumab treatment has not been extensively reported in previous studies.